Följ
Richard M Heywood
Richard M Heywood
Leeds Teaching Hospitals NHS Trust, Cambridge Centre for Brain repair
Verifierad e-postadress på nhs.net
Titel
Citeras av
Citeras av
År
Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit [n] uril
EA Appel, MJ Rowland, XJ Loh, RM Heywood, C Watts, OA Scherman
Chemical communications 48 (79), 9843-9845, 2012
1002012
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone
SGM Piccirillo, I Spiteri, A Sottoriva, A Touloumis, S Ber, SJ Price, ...
Cancer research 75 (1), 194-202, 2015
672015
Characteristics and outcome of patients with DNACPR orders in an acute hospital; an observational study
ZBMC Fritz, RM Heywood, SC Moffat, LE Bradshaw, JP Fuld
Resuscitation 85 (1), 104-108, 2014
362014
The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/HtrA2
F Maus, D Sakry, F Binamé, K Karram, K Rajalingam, C Watts, ...
PLoS One 10 (9), e0137311, 2015
302015
A review of the role of stem cells in the development and treatment of glioma
RM Heywood, HJ Marcus, DJ Ryan, SGM Piccirillo, TMF Al-Mayhani, ...
Acta neurochirurgica 154, 951-969, 2012
242012
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, ...
Journal for immunotherapy of cancer 10 (7), 2022
222022
Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study
A Kawsar, C Edwards, P Patel, RM Heywood, A Gupta, J Mann, ...
British Journal of Dermatology 187 (6), 981-987, 2022
152022
A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR
TF Al-Mayhani, RM Heywood, V Vemireddy, JD Lathia, SGM Piccirillo, ...
Neuro-oncology 21 (6), 719-729, 2019
152019
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities
SH Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, ...
European Journal of Cancer 164, 62-69, 2022
42022
1047P efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
P Bhave, T Ahmed, AN Shoushtari, A Zaremba, JM Versluis, J Mangana, ...
Annals of Oncology 32, S876-S877, 2021
32021
Checkpoint inhibitor associated bullous cutaneous adverse immune-related events: a multicentre observational study
A Kawsar, C Edwards, CA Harwood, R Matin, PC Lorigan, C Harland, ...
2022
73P Characteristics and outcomes of emergency presentations due to immune-mediated toxicities
S Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, T Cooksley, ...
Annals of Oncology 32, S1403-S1404, 2021
2021
P14. 70 BMScope: A systematic mapping review of brain/leptomeningeal metastasis clinical studies from 2010 to 2020
VWT Cheng, R Heywood, R Zakaria, R Burger, A Fitzpatrick, K Zucker, ...
Neuro-Oncology 23 (Supplement_2), ii51-ii51, 2021
2021
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.
SHE Nahm, R Heywood, S Callaghan, P Serra-Bellver, A Gupta, ...
Journal of Clinical Oncology 39 (15_suppl), 6586-6586, 2021
2021
NG2/CSPG4 promotes proliferation and resistance to therapy in glioblastoma multiforme
RM Heywood, C Watts
Annals of Medicine and Surgery 3 (1), 18, 2014
2014
NG2/CSPG4 promotes progression of glioblastoma multiforme by enhancing proliferation and resistance to therapy
RM Heywood
University of Cambridge, 2014
2014
NG2/CSPG4 promotes resistance to therapy in glioblastoma multiforme
R Heywood, C Watts
EUROPEAN JOURNAL OF CANCER 49, S784-S784, 2013
2013
The human sub-ependymal zone harbors glioblastoma precursors and represents a distinct therapeutic target.
SGM Piccirillo, I Spiteri, A Sottoriva, A Touloumis, S Ber, SJ Price, ...
Cancer Research 73 (8_Supplement), 5016-5016, 2013
2013
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–18